×

Race for cholesterol drugs

8:17 AM ET Tue, 2 Sept 2014

A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.